Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00812058 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression
A Phase 2 study, sponsored by Repligen Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT00812058 is a Phase 2 study that has completed, run by Repligen Corporation. The registered enrollment target is 180 participants.
The verdict
NCT00812058, a Phase 2 study, has completed, sponsored by Repligen Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
The purpose of this study is to test a new drug, RG2417, to see how the drug affects symptoms of bipolar I depression and to make sure it is safe in humans.
Interventions
- DRUG Placebo
- DRUG RG2417
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2008-11 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00812058
The ClinicalTrials.gov registry entry for NCT00812058 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Repligen Corporation, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00812058 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00812058 about?
NCT00812058 is a clinical study titled "A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression". The purpose of this study is to test a new drug, RG2417, to see how the drug affects symptoms of bipolar I depression and to make sure it is safe in humans.
What is the current status of trial NCT00812058?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2008-11. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00812058?
The interventions under investigation include: Placebo (DRUG), RG2417 (DRUG).
Who is sponsoring clinical trial NCT00812058?
This trial is sponsored by Repligen Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.